Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry
Espinet, Blanca ; Ferrer, Ana ; Bellosillo, Beatriz ; Nonell, Lara ; Salar, Antonio ; Fernández-Rodríguez, Concepción ; Puigdecanet, Eul\u00e0lia ; Gimeno, Javier ; Garcia-Garcia, Mar ; Vela, Maria Carmen ; Luño, Elisa ; Collado, Rosa ; Navarro, José Tomás ; de la Banda, Esmeralda ; Abrisqueta, Pau ; Arenillas, Leonor ; Serrano, Cristina ; Lloreta, Josep ; Miñana, Belén ; Cerutti, Andrea ; Florensa, Lourdes ; Orfao, Alberto ; Sanz, Ferran ; Solé, Francesc ; Dominguez-Sola, David ; Serrano, Sergio
Resumen: Purpose: According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses the usual, aggressive variants and rare, nonnodal cases with monoclonal asymptomatic lymphocytosis, cyclin D1–positive (MALD1). We aimed to understand the biology behind this clinical heterogeneity and to identify markers for adequate identification of MALD1 cases.
Experimental Design: We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in 24 MCL and 13 MALD1 cases by flow cytometry. Classification and regression trees strategy was used to generate an algorithm based on CD38 and CD200 expression by flow cytometry.
Results: We found 171 differentially expressed genes with enrichment of neoplastic behavior and cell proliferation signatures in MCL. Conversely, MALD1 was enriched in gene sets related to immune activation and inflammatory responses. CD38 and CD200 were differentially expressed between MCL and MALD1 and confirmed by flow cytometry (median CD38, 89% vs. 14%; median CD200, 0% vs. 24%, respectively). Assessment of both proteins allowed classifying 85% (11 of 13) of MALD1 cases whereas 15% remained unclassified. SOX11 expression by qRT-PCR was significantly different between MCL and MALD1 groups but did not improve the classification.
Conclusion: We show for the first time that MALD1, in contrast to MCL, is characterized by immune activation and driven by inflammatory cues. Assessment of CD38/CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. MALD1 should be identified and segregated from the current MCL category to avoid overdiagnosis and unnecessary treatment
Idioma: Inglés
DOI: 10.1158/1078-0432.ccr-13-1077
Año: 2014
Publicado en: CLINICAL CANCER RESEARCH 20, 4 (2014), 1007-1019
ISSN: 1078-0432
Factor impacto JCR: 8.722 (2014)
Categ. JCR: ONCOLOGY rank: 12 / 209 = 0.057 (2014) - Q1 - T1
Tipo y forma: Article (PostPrint)
Exportado de SIDERAL (2025-01-09-14:59:03)
Visitas y descargas
Experimental Design: We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in 24 MCL and 13 MALD1 cases by flow cytometry. Classification and regression trees strategy was used to generate an algorithm based on CD38 and CD200 expression by flow cytometry.
Results: We found 171 differentially expressed genes with enrichment of neoplastic behavior and cell proliferation signatures in MCL. Conversely, MALD1 was enriched in gene sets related to immune activation and inflammatory responses. CD38 and CD200 were differentially expressed between MCL and MALD1 and confirmed by flow cytometry (median CD38, 89% vs. 14%; median CD200, 0% vs. 24%, respectively). Assessment of both proteins allowed classifying 85% (11 of 13) of MALD1 cases whereas 15% remained unclassified. SOX11 expression by qRT-PCR was significantly different between MCL and MALD1 groups but did not improve the classification.
Conclusion: We show for the first time that MALD1, in contrast to MCL, is characterized by immune activation and driven by inflammatory cues. Assessment of CD38/CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. MALD1 should be identified and segregated from the current MCL category to avoid overdiagnosis and unnecessary treatment
Idioma: Inglés
DOI: 10.1158/1078-0432.ccr-13-1077
Año: 2014
Publicado en: CLINICAL CANCER RESEARCH 20, 4 (2014), 1007-1019
ISSN: 1078-0432
Factor impacto JCR: 8.722 (2014)
Categ. JCR: ONCOLOGY rank: 12 / 209 = 0.057 (2014) - Q1 - T1
Tipo y forma: Article (PostPrint)
Exportado de SIDERAL (2025-01-09-14:59:03)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
articulos
Notice créée le 2025-01-07, modifiée le 2025-01-09